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Background
Although a marked proportion of thalassemic patients acquire Torque teno virus (TTV) 
through blood transfusion, its clinical importance is unclear. This study was designed to 
investigate the clinical importance of TTV infection in thalassemic patients with and with-
out hepatitis C virus (HCV) co-infection in Iran.
Methods
In this case-control study, 107 thalassemic patients on chronic transfusion and 107 
healthy individuals were selected. According to HCV and TTV infection status (detected 
by semi-nested PCR), patients were categorized into 4 groups: TTV and HCV negative, 
TTV positive, HCV positive, and TTV and HCV positive. Blood ferritin, alanine amino-
transferase (ALT), and aspartate aminotransferase (AST) levels in these 4 groups were 
assessed.
Results
Approximately half of the thalassemic patients (50.5%) and 27.1% of controls had TTV 
infection. Thalassemic patients had a greater chance of TTV infection compared to the 
control group with a sex-adjusted OR of 4.13 (95% CI=2.28-8.13). The increased levels 
of ALT, AST, and ferritin in the TTV and HCV-infected group were not significantly different 
from those in the TTV and HCV negative group. Co-infection with TTV and HCV did not 
significantly increase ALT, AST, and ferritin levels compared to infection with TTV alone.
Conclusion
Although common in thalassemic patients, TTV infection appears to have a negligible role 
in increasing the severity of liver disease, even when co-infection with HCV occurs.
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INTRODUCTION
  Due to their dependency on blood transfusions, thalasse-
mic patients are prone to transfusion-associated hepatitis, 
as a consequence of transfusion-related iron overload and 
exposure to viruses, which may cause hepatitis. The incidence 
of transfusion-related hepatitis in these patients has been 
substantially reduced since the implementation of blood 
screening for hepatitis B virus (HBV) and hepatitis C virus 
(HCV) nucleic acids and antibodies. However, a considerable 
proportion of thalassemic patients have raised levels of serum 
alanine aminotransferase (ALT), without a known causative 
hepatitis virus [1, 2].
Initially, hepatitis G virus (HGV) was presumed to be 
the causative agent of transfusion-associated non-A-C-hep-
atitis; however, this was not confirmed in subsequent studies. 
In 1997, Nishizawa and co-workers isolated a novel single-s 
tranded DNA virus, designated TT virus (TTV), from patients 
with non A-E transfusion-acquired hepatitis, and which ap-
peared to be associated with non A-G post-transfusion hep-
atitis [3]. This virus was renamed Torque teno virus and 
was classified as a species of the Anellovirus genus in an 
unassigned family that is most closely related to the 
Circoviridae [4]. TTV infects the general population and 
particularly those at risk of parenteral exposure [5-8].Korean J Hematol 2011;46:123-7.
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Transfusion-dependent patients, such as those with tha-
lassemia, are more prone to carry TTV and most infections 
(80%) are of mixed genotypes [2, 9]. The prevalence of TTV 
in thalassemic patients varies in different studies and seems 
to be dependent on the diagnostic technique. Kondili et 
al. used two different sets of primers to detect TTV prevalence 
in 37 pediatric and young adult patients with thalassemia. 
The first primer set found TTV in 73% of thalassemic patients, 
while the second set found TTV DNA in 100% of the patients 
[10]. TTV infection can be detected by polymerase chain 
reaction (PCR), in situ hybridization, and specific antibodies 
to TTV [11]. Most TTV infections appear to occur parent-
erally but a substantial proportion of asymptomatic in-
dividuals never exposed to blood-borne agents and the high 
prevalence of TTV, even among healthy children, implicate 
the fecal-oral route of transmission as being potentially im-
portant [5, 12-14].
However, studies have not yet been able to confirm TTV 
as a primary cause of post-transfusion hepatitis, since most 
TTV-positive (TTV+) patients remain asymptomatic, and 
those progressing towards chronic liver disease are invariably 
co-infected with either HBV or HCV [5]. On the other hand, 
considering the fact that thalassemic patients are prone to 
acquiring various genotypes of TTV as a consequence of 
their life-long dependence on repeated blood transfusions, 
the importance of elucidating the potential role of this virus, 
if any, in development of clinical disease is highly important 
[2]. Hence, although a significant proportion of thalassemic 
patients acquire TTV by transfusion and some have co-in-
fection with HCV, it remains uncertain if HCV and TTV 
co-infection leads to more severe hepatitis compared to TTV 
infection alone [15-20]. The clinical outcome of TTV in 
thalassemic patients is controversial, and there have been 
no previous studies in this regard in Iran. Thus, the current 
study is designed to investigate the prevalence and clinical 
importance of TTV infection in thalassemic patients with 
and without HCV co-infection in Iran.
MATERIALS AND METHODS
In this case-control study, a total of 107 thalassemic pa-
tients, who received regular blood transfusions at the 
Thalassemia Center of Mofid Childrens' Hospital, Tehran, 
Iran, were selected as the patient group. One hundred and 
seven healthy volunteers were categorized as the control 
group. First, TTV DNA was assessed for all the patients 
and controls, and according to the HCV and TTV infection 
test results, cases were categorized into four groups: both 
TTV and HCV negative (TTV-HCV-), TTV positive alone 
(TTV+), HCV positive alone (HCV+), and TTV and HCV 
positive (TTV+HCV+). Blood ferritin, AST, and ALT levels 
in these 4 groups were assessed in order to determine the 
clinical outcome of TTV and HCV infections. In standard 
donor-screening tests, all the samples were negative for HIV, 
human T cell leukemia viruses, and HBV. Informed consent 
for serological studies was obtained from the patients or 
their parents if the patients were under 18 years of age. 
The study protocol was approved by the ethics committee 
of Tehran University of Medical Sciences (TUMS).
1. Virological and biochemical laboratory tests 
Serum ALT and AST levels were measured using an auto-
mated analyzer and values higher than 50 and 40 IU/L, 
respectively, were considered to be abnormal. Serum ferritin 
was determined by ELISA (IMx ferritin assay; Abbott Divi-
sion Diagnostici, Rome, Italy) and because of its high plasma 
levels in thalassemic patients, values higher than 3,000 ng/mL 
were considered to be hyperferritinemia. Anti-HCV status 
was determined by a commercially available second gen-
eration enzyme-linked ELISA (hepatitis C II; Abbott Labora-
tories, North Chicago, IL, USA) and hepatitis B surface anti-
gen (HBsAg) was determined by radioimmune assay (Abbot 
Laboratories, North Chicago, IL, USA). HCV RNA was de-
t e c t e d  b y  R T - P C R  a s  d e s c ribed previously [21-23].
2. Isolation and determination of TTV DNA by PCR
Semi-nested PCR was used to detect serum TTV DNA. 
Specifically, serum DNA purified from an equivalent of 7 
μL of serum was amplified using the following PCR protocol 
in 9600 thermal cycler (Perkin-Elmer, Emeryville, CA, USA); 
1 cycle at 95
oC for 9 min, 35 cycles at 94
oC for 30 s, 58
oC 
for 30 s, 72
oC for 45 s, 1 cycle at 72
oC for 7 min. The 
reaction mix contained 30 pmol of each primer (sense NG059: 
5'-ACA GAC AGA GGA GAA GGC AAC ATG-3', antisense 
NG063: 5'-CTG GCA TTT TAC CAT TTC CAA AGT-3') 
and 2.5 U of AmpliTaq Gold (Perkin-Elmer, Emeryville, 
CA) in a 50 μL reaction volume. Under the same conditions, 
the second round of PCR was performed using a semi-nested 
primer set (sense NG061; 5'-GGC AAC ATG TTA TGGATA 
GAC TGG-3', antisense NG063) and 5 μL of the amplification 
product. Multiple positive and negative controls were in-
cluded in each PCR assay. PCR products were analyzed on 
2% agarose gel with ethidium bromide staining. For all pos-
itive samples of TTV DNA, separate assays were performed 
and sequences of PCR products were confirmed by automated 
sequencing on ABI 373 sequencer (Perkin-Elmer, Foster City, 
CA, USA).
3. Statistical analysis
Results were reported as the mean±standard deviation (SD) 
for quantitative variables and percentages for categorical 
variables. We categorized AST, ALT and ferritin levels into 
normal and abnormal groups using the clinical ranges de-
scribed above. The groups were compared using Student’s 
t-tests for continuous variables and chi-square tests (or 
Fisher’s exact test, if required) for categorical variables. 
Statistical significance was based on two-sided design-based 
tests with P≤0.05 being considered significant. All statistical 
analyses were performed using SPSS version 13 (SPSS Inc., 
Chicago, IL, USA) for Windows. Korean J Hematol 2011;46:123-7.
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Table 1. Demographic and clinical data of 107 thalassemic patients according to TTV and HCV infection.
Characteristics TTV-HCV- (N=37) TTV+HCV- (N=54) TTV-HCV+ (N=4) TTV+HCV+ (N=12)
Age (years) 12.97±5.75 13.93±5.22 19.75±1.26 20.75±3.79
Male gender (%) 56.8 46.3   0.0 75.0
Transfusion duration (months)   19.97±25.89   19.05±24.31   13.75±15.37   23.25±17.19
ALT (＞50 IU/L) (%)   8.1 14.8 25.0 33.3
AST (＞40 IU/L) (%)   8.1 24.1 50.0 50.0
Ferritin (＞3,000 ng/mL) (%) 13.5 22.2 25.0 16.7
Abbreviations: TTV, torque teno virus; HCV, Hepatitis C virus; ALT, alanine-aminotransferase; AST, aspartate-aminotransferase.
Table 2. The mean plasma levels of ALT, AST, and ferritin in 54 TTV-infected thalassemic patients of differing age, sex, and transfusion duration.
Characteristics ALT (IU/L) P AST  (IU/L) P Ferritin (ng/mL) P
Age
   ＜15 years (N=28) 33.4±25.2 0.36 30.28±19.85 0.79 1,596.8±680.8 0.08
   ≥15 years (N=26) 43.4±50.4 32.42±23.57    4,042.8±7,205.3
Sex
   Female (N=29) 30.2±15.7 0.11 26.79±11.85 0.08    2,024.6±1,726.2 0.25
   Male (N=25) 47.5±54.4 37.16±28.27    3,644.5±7,281.3
Transfusion duration
   ＜12 months (N=22) 34.0±19.6 0.40 30.82±16.52 0.79    2,133.1±1,729.6 0.35
RESULTS
In this study, 107 thalassemic patients (51.4% male) with 
a mean age of 14.61±5.96 years and an average transfusion 
duration of 19.64±23.60 months were selected as the patient 
group. A representative sample of 107 healthy volunteers 
(33.6% male) with a mean age of 13.13±6.37 years were 
selected as the control group. According to their HCV and 
TTV infection results, the patient group was divided into 
four subgroups (TTV-HCV-, TTV+, HCV+, and TTV+HCV+). 
TTV infection was found in 27.1% of controls. Nearly two- 
thirds (65.4%) of thalassemic patients carried a virus of which 
approximately half (50.5%) had TTV infection alone and 
11.2% had both TTV and HCV infection. HCV infection 
alone was found in 4 patients (3.7%). 
Demographic and clinical data of the 4 groups is shown 
in Table 1. Seventy-five percent of TTV+HCV+ patients and 
46.3% of TTV+ patients were male. Patients who were co-in-
fected with TTV and HCV were older when compared to 
those infected with TTV alone (20.8±3.8 vs. 14.0±5.8 years, 
P＜0.001) and tended to have been undergoing blood trans-
fusions for longer (23.3±17.2 vs. 19.1±24.3 months, P=0.58), 
although this difference was not statistically significant. 
Abnormal values of serum ALT (＞50 IU/mL) and AST (＞40 
IU/mL) levels were more often found in TTV+HCV+ patients 
compared to the TTV+HCV- group (33.3% vs. 14.8% and 
50.0% vs. 24.1%, respectively). This is in contrast to the 
incidence of hyperferritinemia (＞3,000 ng/mL), which was 
observed more often in the TTV+HCV- group than in 
TTV+HCV+ patients, although was not statistically signifi-
cant. An age ＞15 years, gender, or transfusion duration 
of ＞12 months were not correlated with the incidence of 
infection with TTV alone. However, there was a significant 
relationship between older age (＞15 years) and TTV-HCV 
co-infection (OR=1.86, 95% CI=1.30-2.65), although a similar 
relationship was not found between gender or transfusion 
duration (＞12 months) and TTV-HCV co-infection.
In order to evaluate the influence of age, sex, and trans-
fusion duration on clinical outcome in TTV+ patients, we 
compared mean plasma levels of ALT, AST, and ferritin 
in these patients under these categories (Table 2). However, 
we found no significant differences in these plasma bio-
chemical markers with increased age, transfusion duration, 
or gender (P＞0.05). 
Thalassemic patients had a greater chance of TTV infection 
in comparison to the control group, with a pure OR of 
3.93 (95% CI=2.16-7.13). This relationship was also con-
firmed even when we considered sex as a probable confound-
ing factor (OR=4.13, 95% CI=2.28-8.13), with males being 
significantly more prevalent among TTV patients than unin-
fected controls (51.4% vs. 33.6%, respectively, P=0.012). In 
Table 3, the mean plasma levels of ALT, AST, and ferritin 
in the TTV-HCV-, TTV+HCV-, TTV-HCV+ and TTV+HCV+ 
groups are compared. The increased levels of ALT, AST, 
and ferritin observed in the TTV+HCV- group did not differ 
statistically from those of the TTV-HCV- group. Further-
more, co-infection with TTV and HCV did not significantly 
increase ALT, AST, or ferritin levels when compared with 
infection with either TTV or HCV alone.Korean J Hematol 2011;46:123-7.
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Table 3. Comparison of the mean plasma levels of ALT, AST, and 
ferritin in TTV-HCV-, TTV+HCV-, TTV-HCV+, and TTV+HCV+ 
groups.
TTV-HCV- (N=37) TTV+HCV- (N=54) 　P
ALT (IU/L) 27.71±19.38 38.24±39.30 0.158
AST (IU/L) 27.09±28.94 31.59±21.53  0.410
Ferritin (ng/mL) 2,110.4±1,274.0 2,774.5±5,123.2 0.488
TTV+HCV- (N=54) TTV+HCV+(N=12)
ALT (IU/L) 38.24±39.30 42.58±24.12  0.715
AST (IU/L) 31.59±21.53 45.92±41.38  0.090
Ferritin (ng/mL) 2,774.5±5,123.2 2,324.3±2,473.7 0.778
TTV-HCV+(N=4) TTV+HCV+(N=12)
ALT (IU/L) 38.50±14.27 42.58±24.12  0.75
AST (IU/L) 34.25±12.55 45.92±41.38  0.595
Ferritin (ng/mL) 2,532.5±1,445.5 2,324.3±2,473.7 0.888
DISCUSSION
The potential role and clinical importance of TTV infection 
in liver diseases, as a transfusion-transmitted agent in tha-
lassemic patients and other transfusion-dependent diseases, 
has been discussed since the discovery of the virus in 1997. 
The prevalence of TTV varies among thalassemic patients 
from different nations. Approximately half of the patients 
(50.5%) and more than a quarter of controls (27.1%) were 
found to have TTV infection. Hsu et al. also found 27.0% 
of 122 healthy children in Taiwan to be infected with TTV 
[12]. In our study, thalassemic patients had a greater chance 
of TTV infection in comparison with the control group with 
a common OR of 4.31 (95% CI=2.28-8.13). This could reflect 
the greater importance of the parenteral route for virus trans-
mission that has been noted in previous studies [5, 12, 24]. 
However, among infected subjects in the control group were 
healthy young children without any transfusion history or 
known diseases, suggesting a non-parenteral route of trans-
mission for TTV. Epidemiological studies suggest that the 
main routes of TTV infection are parenteral, oral-fecal, and 
possibly salivary [14].
The prevalence of TTV among thalassemic patients varies 
in different studies and has been reported to be as high 
as 100% [10, 25-27], depending on diagnostic technique and 
specimen type. Chen et al. used peripheral blood mono-
nuclear cells, plasma, saliva, and urine samples from 50 tha-
lassemic patients for TTV detection. They found that all 
50 patients had TTV in one or more specimens and that 
16.0% of patients were positive for all specimen types [28].
In the current study, abnormal levels of ALT and AST 
were observed in a considerable proportion of TTV+ patients 
(14.8% and 24.1%, respectively) and in TTV+HCV+ patients 
(33.3% and 50.0%, respectively). Moreover, abnormal levels 
of these markers were also found in 8.1% of patients without 
TTV or HCV infection. The reason for this is not clear but 
might be explained by liver disease associated with trans-
fusion-related iron overload, the presence of undiagnosed 
TTV genotypes, or other blood-borne agents. Studies by Hu 
and co-workers confirm our findings that there is a higher 
incidence of abnormal ALT and AST levels in TTV+ patients 
(33.6% and 36.7%, respectively) and TTV+HCV+ patients 
(56.6% and 70.0%, respectively) [24]. They concluded that 
ALT, AST, and ferritin levels were invariably lower in TTV- 
patients than in TTV+ patients and that there are significantly 
elevated ferritin and ALT levels with TTV-HCV co-infection 
compared to TTV infection alone [24]. In the current study, 
TTV+HCV- patients tended to have increased levels of ALT 
and AST compared to the TTV-HCV- group, as did TTV+ 
HCV+ patients compared to the TTV+HCV- group, although 
these differences were not statistically significant. Some re-
cent studies also demonstrated that co-infection with TTV 
and HCV in thalassemic patients does not alter the plasma 
profile of biochemical markers when compared with TTV 
infection alone [26]. The same pattern was also found for 
TTV+HCV+ patients compared with those infected with 
HCV alone. However, due to the low prevalence of HCV+ 
patients (4 patients), these findings should be considered 
with caution.
Assessing the severity of liver disease solely by measure-
ments of plasma transaminase levels is inadequate. Histologi-
cal data are also necessary, possibly with an estimated dura-
tion of virus infection. However, due to the lack of histo-
logical studies of patient tissues in the current study, we 
were not able to address this issue. In our study, to enhance 
cost-effectiveness ALT, AST, and ferritin levels were only 
measured in the control group. Regardless of whether TTV 
is a cause of liver disease in thalassemic patients, pathogenic 
mechanisms of the virus need to be rapidly elucidated in 
order to develop new strategies to prevent transmission and 
for therapeutic intervention. Targeted longitudinal studies 
o f  T T V  i n  t h e  f u t u r e  w il l  b e  h e l p f u l  i n  t h i s  r e g a r d  [ 29 ] .  
On the basis of our study, it can be concluded that TTV, 
despite being widely distributed among thalassemic patients, 
appears to have a negligible role in increasing the severity 
of liver disease, even when co-infection with HCV occurs.
REFERENCES
1. Okamoto H, Mayumi M. TT virus: virological and genomic char-
acteristics and disease associations. J Gastroenterol 2001;36:519- 
29.
2. Chen BP, Rumi MG, Colombo M, et al. TT virus is present in a high 
frequency of Italian hemophilic patients transfused with plas-
ma-derived clotting factor concentrates. Blood 1999;94:4333-6.
3. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, 
Mayumi M. A novel DNA virus (TTV) associated with elevated 
transaminase levels in posttransfusion hepatitis of unknown 
etiology. Biochem Biophys Res Commun 1997;241:92-7.
4. Hino S. TTV, a new human virus with single stranded circular 
DNA genome. Rev Med Virol 2002;12:151-8.
5. Poovorawan Y, Tangkijvanich P, Theamboonlers A, Hirsch P. Korean J Hematol 2011;46:123-7.
TTV infection in thalassemic patients 127
Transfusion transmissible virus TTV and its putative role in the 
etiology of liver disease. Hepatogastroenterology 2001;48:256- 
60. 
6. Cossart Y. TTV - a virus searching for a disease. J Clin Virol 
2000;17:1-3.
7. Simmonds P. Transfusion virology: progress and challenges. 
Blood Rev 1998;12:171-7.
8. Blejer JL, Salamone HJ. Is TT virus (TTV) a true hepatitis virus 
cause? Medicina (B Aires) 2000;60:631-8. 
9. Okamoto H, Takahashi M, Nishizawa T, et al. Marked genomic 
heterogeneity and frequent mixed infection of TT virus demon-
strated by PCR with primers from coding and noncoding regions. 
Virology 1999;259:428-36.
10. Kondili LA, Pisani G, Beneduce F, et al. Prevalence of TT virus in 
healthy children and thalassemic pediatric and young adult 
patients. J Pediatr Gastroenterol Nutr 2001;33:629-32.
11. Liweń I, Januszkiewicz-Lewandows k a  D ,  N o w a k  J .  T T  v i -
rus-characteristics, occurrence and routes of transmission. Przegl 
Epidemiol 2002;56:91-9.
12. Hsu HY, Ni YH, Chen HL, Kao JH, Chang MH. TT virus infection 
in healthy children, children after blood transfusion, and children 
with non-A to E hepatitis or other liver diseases in Taiwan. J Med 
Virol 2003;69:66-71. 
13. Davidson F, MacDonald D, Mokili JL, Prescott LE, Graham S, 
Simmonds P. Early acquisition of TT virus (TTV) in an area en-
demic for TTV infection. J Infect Dis 1999;179:1070-6.
14. Yzèbe D, Xueref S, Baratin D, Boulétreau A, Fabry J, Vanhems P. 
TT virus. A review of the literature. Panminerva Med 2002;44: 
167-77. 
15. Tokita H, Murai S, Kamitsukasa H, et al. High TT virus load as an 
independent factor associated with the occurrence of hep-
atocellular carcinoma among patients with hepatitis C virus-re-
lated chronic liver disease. J Med Virol 2002;67:501-9.
16. Meng XW, Komatsu M, Goto T, et al. Clinical significance of TT 
virus in chronic hepatitis C. J Gastroenterol Hepatol 2001;16: 
202-8.
17. Cleavinger PJ, Persing DH, Li H, et al. Prevalence of TT virus in-
fection in blood donors with elevated ALT in the absence of known 
hepatitis markers. Am J Gastroenterol 2000;95:772-6.
18. Yuki N, Kato M, Masuzawa M, et al. Clinical implications of co-
infection with a novel DNA virus (TTV) in hepatitis C virus car-
riers on maintenance hemodialysis. J Med Virol 1999;59:431-6.
19. Charlton M, Adjei P, Poterucha J, et al. TT-virus infection in North 
American blood donors, patients with fulminant hepatic failure, 
and cryptogenic cirrhosis. Hepatology 1998;28:839-42.
20. Zein NN, Arslan M, Li H, et al. Clinical significance of TT virus 
infection in patients with chronic hepatitis C. Am J Gastroenterol 
1999;94:3020-7.
21. Ni YH, Chang MH, Lue HC, et al. Posttransfusion hepatitis C virus 
infection in children. J Pediatr 1994;124:709-13.
22. Lai MW, Chang MH, Hsu HY. Non-A, non-B, non-C hepatitis: its 
significance in pediatric patients and the role of GB virus-C. J 
Pediatr 1997;131:536-40.
23. Chen HL, Chang MH, Ni YH, Hsu HY, Kao JH, Chen PJ. Hepatitis 
G virus infection in normal and prospectively followed post-
transfusion children. Pediatr Res 1997;42:784-7.
24. Hu YW, Al-Moslih MI, Al Ali MT, et al. Clinical outcome of fre-
quent exposure to Torque Teno virus (TTV) through blood trans-
fusion in thalassemia patients with or without hepatitis C virus 
(HCV) infection. J Med Virol 2008;80:365-71. 
25. Sampietro M, Tavazzi D, Martinez di Montemuros F, et al. TT virus 
infection in adult beta-thalassemia major patients. Haematologica 
2001;86:39-43. 
26. Ozyürek E, Ergünay K, Kuskonmaz B, et al. Transfusion-trans-
mitted virus prevalence in Turkish patients with thalassemia. 
Pediatr Hematol Oncol 2006;23:347-53. 
27. Erensoy S, Sayiner AA, Türkoğlu S, et al. TT virus infection and 
genotype distribution in blood donors and a group of patients from 
Turkey. Infection 2002;30:299-302.
28. Chan PK, Chik KW, Li CK, et al. Prevalence and genotype dis-
tribution of TT virus in various specimen types from thalassaemic 
patients. J Viral Hepat 2001;8:304-9. 
29. Dhenain M, Boulétreau A, Bourguignon F, et al. The TT virus: re-
view of the literature. Clin Invest Med 2000;23:355-65.